AGE VERIFICATION

Please certify that you are 19 of age or older in order to access this website.

Yes, I am over 19 No, I am under 19

Latest News/Research

Psilocybin mushrooms spills from a storage jar on wooden surface, top view, flat lay. Psychedelic magic mushroom Golden Teacher. Microdosing concept. Psychotropic therapy.
Research Summary

Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands

The paper "Psychedelic Integration Challenges: Participant Experiences After a Psilocybin Truffle Retreat in the Netherlands" explores the experiences and challenges faced by participants during the integration process after attending a psilocybin truffle retreat. Through qualitative analysis of semi-structured interviews, the study identifies four primary themes: difficulty implementing insights, social challenges, emotional challenges, and a lack of structured support. The findings emphasize the need for adequate support and resources during the integration process to maximize the potential benefits of psychedelic therapies and enhance the understanding of their therapeutic potential.
by The ShrumLane Team January 17, 2023
Albino A strain. White background. Psilocybin mushroom. Close up Magic shroom. Dry Psilocybe cubensis. Psychedelic drug. Psilocybin Mushroom.
Research Summary

Psychedelics for Patients With Cancer: A Comprehensive Literature Review

This comprehensive literature review explores the potential benefits and risks of using psychedelics, such as LSD and psilocybin, as a treatment for cancer patients experiencing anxiety, depression, and existential distress. The paper delves into the historical context, pharmacological mechanisms, and clinical trials that demonstrate the potential of these substances in alleviating cancer-related distress, while also highlighting the limitations and potential risks associated with their use. Further research is needed to establish best practices for psychedelic-assisted therapy and to identify the patients who would benefit the most from this approach.
by The ShrumLane Team January 13, 2023
psychedelic mushrooms
Research Summary

Single-Dose Psilocybin-Assisted Therapy In Major Depressive Disorder: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial

This placebo-controlled, double-blind, randomized clinical trial investigated the efficacy of single-dose psilocybin-assisted therapy for treating major depressive disorder (MDD) in 59 participants. The results demonstrated that a single 25 mg dose of psilocybin, administered alongside supportive psychotherapy, led to significant and sustained reductions in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), compared to the placebo group. The study also reported a favorable safety profile for psilocybin, with mild and transient side effects. Although the trial provides compelling evidence for psilocybin-assisted therapy as a promising new treatment approach for depression, further research is needed to confirm these findings in larger and more diverse populations and assess long-term safety and efficacy.
by The ShrumLane Team December 29, 2022
Psychedelic psilocybin mushrooms Golden Teacher on mycelium block, close-up. Psilocybe Cubensis raw mushrooms isolated on white background. Micro-dosing concept.
Research Summary

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

This study investigates the efficacy of single-dose psilocybin-assisted therapy for patients with major depressive disorder (MDD) through a double-blind, randomized, placebo-controlled clinical trial. The findings reveal that patients receiving psilocybin-assisted therapy experienced significant improvements in depression severity, anxiety levels, and overall functioning, with effects maintained up to six months post-treatment. These results contribute to the growing body of evidence supporting the potential of psychedelic-assisted therapy, particularly single-dose psilocybin treatment, as a promising option for individuals suffering from MDD.
by The ShrumLane Team December 29, 2022
Mycelium block of psychedelic psilocybin mushrooms Golden Teacher. Micro growing of psilocybe cubensis on black background. Macro view; close-up. Micro-dosing concept.
Research Summary

Psychotherapists’ openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment

This paper explores the attitudes and openness of psychotherapists towards the integration of psilocybin-assisted therapy (PAT) into mental health treatment, revealing that the majority (71%) are open to its use if it becomes legally available. Factors associated with openness include younger age, higher education, previous experience with psychedelics, and spiritual inclination. However, concerns about potential risks, adverse effects, commodification, and the need for proper training and supportive clinical environments are also identified as critical considerations for the safe and effective implementation of PAT.
by The ShrumLane Team December 22, 2022
12-month follow-up 1 5-HT2A receptor 2 abstinence rates 1 acute effects 1 addiction 3 addiction treatment 1 advanced cancer 1 adverse effects/events/reactions 3 alcohol consumption 1 Alcohol Use Disorder (AUD) 4 alternative medications 1 alternative treatment 1 antidepressants 3 anxiety 18 athletes 1 attitudes 1 attitudes towards death 1 ayahuasca 1 bad trips 1 bipolar disorder 1 body dysmorphic disorder (BDD) 1 body mass index (BMI) 1 brain network connectivity 1 breakthrough therapy 4 cancer patients 4 clinical applications 1 clinical environment 1 clinical trial 2 clinical trials 4 clinically meaningful response 1 cluster headache 1 co-occurring disorders 1 cognitive functioning 1 cognitive-behavioral therapy (CBT) 3 commodification 1 connectedness 1 controlled trial 1 courses 1 decriminalization 1 default mode network 1 dependence 1 depression 17 depression severity 1 depressive symptoms 0 DMT 1 double-blind 5 efficacy 4 emotional challenges 1 emotional eating 1 emotional release 1 emotional well-being 1 empathy 2 end-of-life care 1 ethical implications 1 existential distress 2 food addiction 1 functioning 1 guide 2 guided trip 1 hallucinogen persisting perception disorder (HPPD) 1 hallucinogenic mushrooms 1 Hamilton Depression Rating Scale 2 harm potential 1 harm reduction 1 headache frequency 1 headache intensity 1 healing process 1 heavy drinking days 1 history 1 implementing insights 1 improved mood 1 indigenous cultures 1 individual differences 1 individual factors 1 interconnectedness 1 international survey 0 introspection 1 Jamaica 1 lasting antidepressant effect 1 legal barriers 1 legal hurdles 1 legalization 1 life-threatening cancer 1 limitations 3 long COVID 1 long-term effects 1 low-dose pulse regimen 1 LSD 3 magic mushrooms 7 mainstream healthcare 1 major depression 1 major depression disorder 1 major depressive disorder (MDD) 7 manic episodes 0 manic symptoms 1 MDMA 3 meaning response 1 mechanism of action 1 mental health 10 mental health treatment 2 meta-analysis 3 microdosing 2 Moms on Mushrooms 1 Montgomery-Asberg Depression Rating Scale (MADRS) 2 mood regulation 0 mycotherapy 1 Netherlands 1 neurobiological mechanisms 0 neuroplasticity 6 nonrandomized controlled trial 1 novel treatment 1 obesity 1 obsessive-compulsive disorder (OCD) 2 online community 1 openness 1 paranoia 1 participant experiences 1 performance enhancement 1 personal experience 2 personal growth 2 pharmacotherapy 2 physical pain 1 physiological responses 1 pilot study 1 placebo-controlled 4 post-traumatic stress disorder (PTSD) 7 potential risks 1 psilocybin 25 Psilocybin therapy 2 psilocybin truffle retreat 1 psilocybin-assisted psychotherapy 1 psilocybin-assisted therapy 16 psychedelic integration 1 psychedelic research 1 psychedelic-assisted therapy 3 psychedelics 6 psychiatric disorders 1 psychiatric illness 1 psycho-social-spiritual well-being 2 psychological distress 1 psychological flexibility 1 psychological growth 1 psychological responses 1 psychotherapists 1 psychotherapy 6 qualitative analysis 2 quality of life 7 randomized 1 randomized controlled trial 8 rapport 2 regulatory barriers/challenges 2 relationships 1 remission 1 research 2 research implications 1 resilience 1 resistance 1 retreat setting 1 risks 5 safety 8 scalable model 1 scientific research 1 self-awareness 1 self-reflection 1 self-report 0 serotonergic system 2 serotonin 2A receptors 1 serotonin agonist 1 set and setting 1 severe depression 1 side effects 3 single-dose 1 social challenges 1 spiritual experiences 3 spiritual well-being 2 standardized treatment protocols 1 stress 1 stress-induced weight gain 1 structured support 1 substance 1 substance use disorders 2 suicidality 1 survey 1 symptom reduction 1 systematic review 1 thematic analysis 1 therapeutic outcomes 2 therapeutic potential/benefits 7 therapeutic relationship 2 therapeutic settings/environment 2 toxicity 1 training 1 transformative experiences 2 treatment 1 treatment efficacy 3 treatment option 1 treatment-resistant depression 4 vulnerable populations 1 web-based questionnaire 0 wellness 1 Yale-Brown Obsessive Compulsive Scale 1
Home
Shop
0 Wishlist
Search
More
More